🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against superbug strains of the infection, according to health experts.

A Global Health Concern

Cases of gonorrhoea are on the rise around the world, with estimates suggesting in excess of 82 million new cases annually. Particularly high rates are observed in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Secure Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in concurrent days. This treatment, which is additionally indicated for UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This approval represents a major breakthrough in the treatment of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

Based on data released by a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This puts it on an comparable level with the typical regimen, which involves an injection and a pill. The trial included nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to register and commercialise the drug in many regions with limited resources.

Medical professionals treating patients have expressed positive views. Access to a one-pill regimen such as this is described as a "revolutionary step" for gonorrhoea control. This is viewed as vital to lessen the impact of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.